Premium
Long‐term efficacy of biologics in dermatology
Author(s) -
CasteloSoccio Leslie,
Van Voorhees Abby S.
Publication year - 2009
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2008.01213.x
Subject(s) - medicine , efalizumab , etanercept , adalimumab , dermatology , rituximab , infliximab , psoriasis , psoriatic arthritis , secukinumab , clinical trial , ustekinumab , intensive care medicine , rheumatoid arthritis , plaque psoriasis , disease , lymphoma
Chronic dermatologic diseases affect millions of people. The long‐term nature of these diseases creates psychological and financial burden as well as substantially impacts patients' quality of life. Biologics, including adalimumab, etanercept, alefacept, efalizumab, and infliximab, are the newest therapeutic agents in the treatment of moderate‐to‐severe psoriasis and psoriatic arthritis and have been used in a variety of other dermatologic diseases. These agents act relatively quickly and effectively in 12‐week clinical trials. Because these agents are used to treat patients for longer than 12 weeks, there is a need to review the safety and efficacy of these agents over longer periods of time. Many levels of evidence are available for biologics including high level of evidence from large, randomized, double‐blind, placebo‐controlled clinical studies. This review focuses on the available data for efficacy and safety for greater than 24 weeks of therapy. The studies supporting the use of rituximab and intravenous immunoglobulin in autoimmune blistering diseases are also presented in this review.